Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of “Buy” by Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been assigned an average rating of “Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $51.60.

Several research firms recently weighed in on TARS. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Oppenheimer reiterated an “outperform” rating and set a $63.00 price objective (up from $61.00) on shares of Tarsus Pharmaceuticals in a research note on Friday, August 9th.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Cowen AND Company LLC boosted its stake in Tarsus Pharmaceuticals by 3.5% in the 2nd quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock worth $59,725,000 after purchasing an additional 74,855 shares during the period. Vanguard Group Inc. boosted its position in shares of Tarsus Pharmaceuticals by 14.5% during the first quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock worth $66,398,000 after acquiring an additional 231,131 shares during the last quarter. Jennison Associates LLC purchased a new position in Tarsus Pharmaceuticals during the first quarter valued at $48,380,000. Assenagon Asset Management S.A. increased its holdings in Tarsus Pharmaceuticals by 7.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock valued at $37,536,000 after acquiring an additional 77,825 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its stake in Tarsus Pharmaceuticals by 1,113.5% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 898,000 shares of the company’s stock worth $32,642,000 after purchasing an additional 824,000 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Up 6.3 %

Tarsus Pharmaceuticals stock opened at $47.30 on Monday. Tarsus Pharmaceuticals has a 52-week low of $14.48 and a 52-week high of $48.60. The company has a market cap of $1.80 billion, a P/E ratio of -10.56 and a beta of 1.00. The company has a quick ratio of 6.99, a current ratio of 7.03 and a debt-to-equity ratio of 0.28. The business has a 50-day simple moving average of $33.97 and a two-hundred day simple moving average of $31.50.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative net margin of 180.00% and a negative return on equity of 63.99%. The business had revenue of $40.81 million during the quarter, compared to analysts’ expectations of $31.30 million. During the same period in the prior year, the company earned ($1.17) earnings per share. Analysts predict that Tarsus Pharmaceuticals will post -3.71 EPS for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.